Tema Oncology ETF
NASDAQ · us_market
No AI summary generated yet for this ticker.
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
FDA accepts Cogent Biosciences' NDA for bezuclastinib in NonAdvSM. PDUFA date set for Dec 30, 2026. COGT stock rises on the news.
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.
NEW YORK, December 02, 2025--Tema ETFs ("Tema"), the New York-based manager of innovative exchange-traded funds (ETFs), is pleased to announce the Tema Oncology ETF ("CANC") has surpassed $100m in assets under management (AUM) two years since launch. The CANC ETF invests in leading oncology companies and cancer therapies and is the only pure-play oncology focused ETF in the world, managed by Dr. David Song MD, PhD, CFA.1
Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.
Be thankful for this year's resilient ETFs -- BWET, LITP, PINK and CANC -- which shined despite volatility, tariffs, AI worries and Fed shifts.
Large pharma companies are facing severe patent cliffs, where blockbuster drugs lose exclusivity and revenue plummets.
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.